Expertise in
12
conditions

Dr. Paul Orchard

Hematology | Oncology
University Of Minnesota Masonic Children's Hospital
420 Delaware St SE, 
Minneapolis, MN 
38 Years of Experience
Expertise in
12
conditions
University Of Minnesota Masonic Children's Hospital
420 Delaware St SE, 
Minneapolis, MN 

Overview

Paul Orchard is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. He has been practicing medicine for over 38 years.

Dr. Orchard is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Adrenoleukodystrophy (ALD), Adrenal Insufficiency Pediatric, Metachromatic Leukodystrophy, Bone Marrow Transplant, and Osteotomy.

He is actively involved in clinical research, co-authoring 164 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in MN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO

Locations

University of Minnesota Masonic Children's Hospital
420 Delaware St SE, Minneapolis, MN 55455

Additional Areas of Focus

Dr. Orchard has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2026
Intervention Type: Drug, Biological
Study Drugs: Fludarabine, Busulfan, Anti-Thymocyte Globulin, Thiotepa, Rituximab, Alemtuzumab, N-Acetylcysteine, Celecoxib, Vitamin E, Alpha Lipoic Acid
Study Phase: Phase 2
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Enrollment Status: Terminated
Publish Date: March 03, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Genetic
Study Drug: Elivaldogene Autotemcel
Study Phase: Phase 3
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Genetic
Study Phase: Phase 2/Phase 3
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
Enrollment Status: Terminated
Publish Date: May 21, 2020
Intervention Type: Genetic
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).
Enrollment Status: Terminated
Publish Date: September 27, 2018
Intervention Type: Drug
Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy
Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy
Enrollment Status: Withdrawn
Publish Date: July 06, 2018
View 6 Less Clinical Trials

164 Total Publications

CSF and plasma neuro-biomarker dynamics after gene therapy for cerebral adrenoleukodystrophy.
CSF and plasma neuro-biomarker dynamics after gene therapy for cerebral adrenoleukodystrophy.
Journal: Molecular therapy. Advances
Published: May 15, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Margaret Macmillan
Hematology | Oncology
Expertise in
14
conditions
Dr. Margaret Macmillan
Hematology | Oncology
Referral may be required

University Of Minnesota Medical Center Fairview Riverside

2450 Riverside Ave, 
Minneapolis, MN 
 (0.6 miles away)
612-365-4100
Languages Spoken:
English
See accepted insurances

Margaret Macmillan is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Macmillan is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Congenital Aplastic Anemia, Fanconi Anemia, Graft Versus Host Disease (GvHD), Aplastic Anemia, and Bone Marrow Transplant.

Expertise in
30
conditions
Dr. Mark Reding
Hematology | Oncology
Expertise in
30
conditions
Dr. Mark Reding
Hematology | Oncology
Referral may be required

Fairview Pharmacy Hemophilia Services

2512 S 7th St Ste 105, 
Minneapolis, MN 
 (0.7 miles away)
612-273-5005
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Reding is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Reding is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Splenectomy, and Bone Marrow Transplant.

Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Referral may be required

Fairview Pharmacy Services LLC

516 Delaware St SE, 
Minneapolis, MN 
 (0.2 miles away)
612-273-2800
Languages Spoken:
English
See accepted insurances

Mukta Arora is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Arora is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Paul Orchard

How do I make an appointment with Dr. Paul Orchard?

You can book an appointment with Dr. Paul Orchard by calling their office at 612-626-2313. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul Orchard a top-rated expert for Adrenoleukodystrophy (ALD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul Orchard is classified as an Elite expert for Adrenoleukodystrophy (ALD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul Orchard specialize in?

While Dr. Paul Orchard is a Hematology, they have specific expertise in Adrenoleukodystrophy (ALD), Adrenal Insufficiency Pediatric, and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Paul Orchard participate in research or clinical trials?

Yes. Dr. Paul Orchard has published 164 articles and abstracts on conditions like Adrenoleukodystrophy (ALD). You can view a list of Dr. Paul Orchard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul Orchard accept my insurance?

Dr. Paul Orchard accepts most major insurance plans, including Blue Cross Blue Shield and HealthPartners. We recommend calling the office directly at 612-626-2313 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Orchard's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile